PUBLICATION

Preclinical

2026/04

[OCT-648] Development of Potent and Selective NUAK1 Inhibitors that Attenuate TGF-β–Induced and UUO-Driven Renal Fibrosis via YAP Pathway Modulation

ISN WCN 2026 · Poster P522 · Yoon J, et al.

Preclinical

2025/04

[OCT-598] Inhibition of PGE2 signaling by an EP2/4 dual antagonist OCT-598 prevents acquisition of therapy-resistance and tumor relapse

AACR 2025 · Abstract #3069 · Lee Y, et al.

Preclinical

2025/01

[ADEL-Y01] Preclinical efficacy and rationale of targeting lysine280-acetylated tau for Alzheimer’s disease therapy with ADEL-Y01, humanized monoclonal antibody

Alzheimer's & Dementia, 2024 · 20(Suppl 6):e088589 (AAIC) · Kim MS, et al.

Preclinical

2023/04

[OCT-598] OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune response in combination with SoC chemo- and immunotherapies

AACR 2023 · Abstract #3234 · Lee Y, et al.

Preclinical

2023/03

[Cevidoplenib] A novel selective spleen tyrosine kinase inhibitor SKI-O-703 ameliorates lupus nephritis and serum-induced arthritis in murine models

Clin Exp Immunol, 2023 · Cho S, et al.

Preclinical

2021/12

[Denfivontinib] SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models

Clin Transl Immunology, 2021 Dec 29;11(1):e1364

Preclinical

2017/02

[Lazertinib] Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer

Cancer Res, 2017 · 77(5):1200–1211 · Rho JK, et al.

Preclinical

2016/12

YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC

J Thorac Oncol, 2017 · 12(1 Suppl):S1265–S1266 · Hong MH, et al.

Preclinical

2016/10

[Cevidoplenib] Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs

FEBS J. 2016 Oct;283(19):3613-3625

Preclinical

2015/10

[Cevidoplenib] Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors

Bioorg Med Chem Lett. 2015 Oct 15;25(20):4441-6.

Preclinical

2014/04

[Denfivontinib] G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia

Blood, 2014 · 123(14):2209–2219 · Hee Kyu Lee, et al.

Preclinical

2013/07

[SKI-O-068] Crystal Structure of Pim1 Kinase in Complex with a Pyrido[4,3-D]Pyrimidine Derivative Suggests a Unique Binding Mode

PLoS One. 2013 Jul 31;8(7):e70358.